Search

Search Results

• DISTRIBUTION OF DNA DAMAGE REPAIR GENE POLYMORPHISM hOGG1, XRCC1 and p53 AMONG SICKLE CELL DISEASE PATIENTS IN INDIA

  Sudhansu Sekhar Nishank

  e2015046

  2015-07-02

  https://doi.org/10.4084/mjhid.2015.046

  1656

  PDF: 849

  HTML: 1544

  Table Genotype and allele frequencies of hOGG1 codon 326 Ser>Cys and p53 72Arg>Pro polymorphisms among SCD patients and control group: 224

• THE IMPORTANCE OF EPIGENETIC ALTERATIONS IN THE DEVELOPMENT OF EPSTEIN-BARR VIRUS-RELATED LYMPHOMAS

  Maria Takacs, Judit Segesdi, Ferenc Banati, Anita Koroknai, Hans Wolf, Hans Helmut Niller, Janos Minarovits

  e2009012

  https://doi.org/10.4084/mjhid.2009.012

  1157

  PDF: 559

  HTML: 3218

• MOLECULAR PATHOGENESIS OF SECONDARY ACUTE PROMYELOCYTIC LEUKEMIA

  Melanie Joannides, Ashley N Mays, Anita R Mistry, Syed Khizer Hasan, Andreas Reiter, Joseph L Wiemels, Carolyn A Felix, Francesco Lo-Coco, Neil Osheroff, Ellen Solomon, David Grimwade

  e2011045

  2011-10-24

  https://doi.org/10.4084/mjhid.2011.045

  3208

  PDF: 949

  HTML: 6621

  Untitled: 287

  Untitled: 246

  Untitled: 263

  Untitled: 268

• CLONAL HEMATOPOIESIS: ROLE IN HEMATOLOGIC NON-HEMATOLOGIC MALIGNANCIES CLONAL HEMATOPOIESIS AND MALIGNANCIES

  Ugo Testa, Dr. Germana Castelli, Dr. Elvira Pelosi

  e2022069

  2022-08-27

  https://doi.org/10.4084/MJHID.2022.069

  3446

  PDF: 1012

  HTML: 4237

• DNA Repair Genes and Chronic Myeloid Leukemia: XPD (751), XRCC1 (399), XRCC4-Intron 3, XRCC4 (1394) Gene Polymorphisms Polymorphisms of DNA Repair Genes in CML

  Istemi SERIN, Mustafa PEHLIVAN, Kursat OZDILLI, Fatma OGUZ SAVRAN, Gaye TOMATIR, Sacide PEHLIVAN

  e2021020

  2021-02-26

  https://doi.org/10.4084/mjhid.2021.020

  1240

  PDF: 518

  HTML: 287

• THERAPY-RELATED MYELOID NEOPLASMS IN CHRONIC LYMPHOCYTIC LEUKEMIA AND WALDENSTROM MICROGLOBULINEMIA

  Francesca Ricci, Alessandra Tedeschi, Marco Montillo, Enrica Morra

  e2011031

  2011-07-08

  https://doi.org/10.4084/mjhid.2011.031

  2426

  PDF: 1035

  HTML: 2469

• THERAPY-RELATED MYELOID NEOPLASMS: PREDISPOSITION AND CLONAL EVOLUTION T-AML predisposition

  Emiliano Fabiani, Dr. Falconi, Dr. Cristiano, Dr. Hajrullaj, Dr. Falconi, Prof. Leone, Prof. Voso

  e2023064

  2023-10-30

  https://doi.org/10.4084/MJHID.2023.064

  1577

  PDF: 1008

  HTML: 264

• THERAPEUTIC GENE EDITING FOR HEMOGLOBINOPATHIES Gene therapy for Hemoglobinopathies.

  Ugo Testa, Giuseppe Leone, Prof. M.D. Cappellini

  e2024068

  2024-08-31

  https://doi.org/10.4084/MJHID.2024.068

  2363

  PDF: 1430

  Html: 481

• POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDERS: ROLE OF VIRAL INFECTION, GENETIC LESIONS AND ANTIGEN STIMULATION IN THE PATHOGENESIS OF THE DISEASE

  Daniela Capello, Gianluca Gaidano

  e2009018

  https://doi.org/10.4084/mjhid.2009.018

  1444

  PDF: 504

  HTML: 18635

  Figure 1: 207

  Figure 2: 191

  Figure 3: 206

  Figure 4: 237

  Figure 5: 211

• TP53-MUTATED MYELODYSPLASIA AND ACUTE MYELOID LEUKEMIA TP53 in MDS and AML

  Ugo Testa, Dr. Germana Castelli, Dr. Elvira Pelosi

  e2023038

  2023-06-29

  https://doi.org/10.4084/MJHID.2023.038

  2427

  PDF: 1897

  HTML: 1012

• WHO HAS THERAPY-RELATED AML?

  Robert Gale, John M. Bennett, F. Owen Hoffman

  e2017025

  2017-03-01

  https://doi.org/10.4084/mjhid.2017.025

  3351

  PDF: 4385

  HTML: 882

• EPIDEMIOLOGY OF THERAPY-RELATED MYELOID NEOPLASMS IN THE NORDIC COUNTRIES

  Kjeld Schmiegelow

  e2011020

  2011-05-16

  https://doi.org/10.4084/mjhid.2011.020

  2398

  PDF: 889

  HTML: 1706

  Figure 1: 254

  Table 1: 258

• ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR ADULT PATIENTS WITH FANCONI ANEMIA.

  hosein kamranzadeh fumani, Mohammad Zokaasadi, Amir Kasaeian, Kamran Alimoghaddam, Asadollah Mousavi, Babak Bahar, Mohammad Vaezi, Ardeshir Ghavamzadeh

  e2016054

  2016-11-01

  https://doi.org/10.4084/mjhid.2016.054

  4080

  PDF: 947

  HTML: 811

• GENE THERAPY IN THALASSEMIA AND HEMOGLOBINOPATHIES

  Laura Breda, Roberto Gambari, Stefano Rivella

  e2009008

  2009-11-16

  1410

  PDF: 463

  HTML: 3157

• TREATMENT OF ACUTE MYELOID LEUKEMIA WITH 20-30% BONE MARROW BLASTS

  Luca Maurillo, Francesco Buccisano, Maria Ilaria Del Principe, Chiara Sarlo, Luigi Di Caprio, Concetta Ditto, Federica Giannotti, Daniela Nasso, Eleonora Ceresoli, Massimiliano Postorino, Marco Refrigeri, Sergio Amadori, Adriano Venditti

  e2013032

  2013-06-03

  https://doi.org/10.4084/mjhid.2013.032

  3057

  PDF: 1089

  HTML: 5666

• TRANSCRIPTOME ANALYSIS OF BETA-CATENIN-RELATED GENES IN CD34+ HAEMATOPOIETIC STEM AND PROGENITOR CELLS FROM PATIENTS WITH AML Transcriptome analysis of beta-catenin-related genes in AML

  Buket Altinok Gunes, Tulin OZKAN, Aynur Karadag Gurel, Semih Dalkilic, Nevin Belder, Zeynep Ozkeserli, Hilal Ozdag Sevgili, Meral Beksac, Nilgun Sayinalp, Abdullah Munci Yagci, Asuman Sunguroglu

  e2024058

  2024-06-29

  https://doi.org/10.4084/MJHID.2024.058

  1203

  PDF: 1239

  Suppl. Files: 604

  HTML: 106

• DOWNREGULATION OF STEAROYL-COA DESATURASE 1 (SCD-1) PROMOTES RESISTANCE TO IMATINIB IN CHRONIC MYELOID LEUKEMIA Downregulation of Scd-1 in Chronic Myeloid Leukemia

  Buket Altinok Gunes, Yalda Hekmatshoar, Tulin Ozkan, Sureyya Bozkurt, O.Sena Aydos, Yahya Buyukasik, Elifcan Aladag, Asuman Sunguroglu

  e2023008

  2023-01-01

  https://doi.org/10.4084/MJHID.2023.008

  1553

  PDF: 1332

  HTML: 531

• RECENT ADVANCES IN THE DEFINITION OF THE MOLECULAR ALTERATIONS OCCURRING IN MULTIPLE MYELOMA MOLECULAR ALTERATIONS OCCURRING IN MM

  Ugo Testa, Elvira Pelosi, Germana Castelli, Giuseppe Leone

  e2023062

  2024-06-29

  https://doi.org/10.4084/MJHID.2024.062

  1401

  PDF: 1146

  HTML: 271

• GENETIC PREDISPOSITION TO HEMATOLOGIC MALIGNANCIES IN CHILDHOOD AND ADOLESCENCE

  Francesco Fabozzi, Angela Mastronuzzi

  e2023032

  2023-04-28

  https://doi.org/10.4084/MJHID.2023.032

  2169

  PDF: 582

  HTML: 620

• THE IMPORTANCE OF TARGETED NEXT-GENERATION SEQUENCING USAGE IN CYTOGENETICALLY NORMAL MYELOID MALIGNANCIES Targeted next-generation sequencing usage in cytogenetically normal myeloid malignancies

  Emine Atli, Rasime Kalkan, Cisem Mail, Damla Eker, Ufuk Demirci, Selma Demir, Sinem Yalcintepe, Hakki Onur Kirkizlar, Engin Atli, Hakan Gurkan, Ahmet Muzaffer Demir

  e2021013

  2021-01-01

  https://doi.org/10.4084/mjhid.2021.013

  2423

  PDF: 641

  HTML: 380

• NPM1 MUTATED, BCR-ABL1 POSITIVE MYELOID NEOPLASMS: REVIEW OF LITERATURE NPM1 mutated, BCR-ABL1 positive myeloid neoplasms

  Gianfranco Catalano, Pasquale Niscola, Cristina Banella, Daniela Diverio, Malgorzata Monika Trawinska , Stefano Fratoni, Rita Iazzoni, Paolo de Fabritiis, Elisabetta abruzzese, Nelida Ines Noguera

  e2020083

  2020-10-27

  https://doi.org/10.4084/mjhid.2020.083

  1865

  PDF: 1257

  HTML: 359

• OUTLINE OF IRON METABOLISM, WITH EMPHASIS TO ERYTHROID CELLS iron Metabolism

  Ugo Testa, Elvira Pelosi, Germana Castelli

  e2025067

  2025-08-31

  https://doi.org/10.4084/MJHID.2025.067

  2505

  PDF: 1381

  Html: 1089

• HEPATITIS C VIRUS INFECTION AND LYMPHOMA

  Emmanuel Bachy, Caroline Besson, Felipe Suarez, Olivier Hermine

  e2010004

  2010-03-25

  https://doi.org/10.4084/mjhid.2010.004

  1137

  PDF: 718

  HTML: 7884

• SIMILARITIES OF ELDERLY AND THERAPY-RELATED AML

  Francesco D'Alò, Luana Fianchi, Emiliano Fabiani, Marianna Criscuolo, Mariangela Greco, Francesco Guidi, Livio Pagano, Giuseppe Leone, Maria Teresa Voso

  e2011052

  2011-11-28

  https://doi.org/10.4084/mjhid.2011.052

  3855

  PDF: 973

  HTML: 6888

• THERAPEUTIC OPTIONS FOR PATIENTS WHO ARE NOT ELIGIBLE FOR INTENSIVE CHEMOTHERAPY

  Elihu Estey

  e2013050

  2013-07-12

  https://doi.org/10.4084/mjhid.2013.050

  2284

  PDF: 816

  HTML: 1649

• IS IT POSSIBLE TO PREDICT TUMOR PROGRESSION THROUGH GENOMIC CHARACTERIZATION OF MONOCLONAL GAMMOPATHY AND SMOLDERING MULTIPLE MYELOMA? MONOCLONAL GAMMOPATHY AND SMOLDERING MULTIPLE MYELOMA

  Ugo Testa, Prof. Leone, Dr. Elvira Pelosi, Dr. Germana Castelli, Prof, Valerio De Stefano

  e2024044

  2024-04-30

  https://doi.org/10.4084/MJHID.2024.044

  2683

  PDF: 1251

  HTML: 171

• Complex and Multifaceted Therapy-Related Myeloid Neoplasm Following Laryngeal Cancer Treated with Cisplatin and Radiotherapy

  Pasquale Niscola

  e2013030

  2013-04-16

  https://doi.org/10.4084/mjhid.2013.030

  1271

  PDF: 812

  HTML: 1540

  Figure 1: 256

  Figure 2: 260

• INCIDENCE OF ACUTE MYELOID LEUKEMIA AFTER BREAST CANCER

  Caterina Giovanna Valentini, Luana Fianchi, Maria Teresa Voso, Morena Caira, Giuseppe Leone, Livio Pagano

  e2011069

  2011-12-22

  https://doi.org/10.4084/mjhid.2011.069

  3460

  PDF: 1039

  HTML: 3016

• SYSTEMIC MASTOCYTOSIS: MOLECULAR LANDSCAPE AND IMPLICATIONS FOR TREATMENT

  Cecilia Monaldi, Sara De Santis, Manuela Mancini, Samantha Bruno, Michele Cavo, Simona Soverini

  e2021046

  2021-06-28

  https://doi.org/10.4084/MJHID.2021.046

  1546

  PDF: 806

  HTML: 471

• IMMUNOGLOBULIN GENE REPERTOIRE IN CHRONIC LYMPHOCYTIC LEUKEMIA: INSIGHT INTO ANTIGEN SELECTION AND MICROENVIRONMENTAL INTERACTIONS

  Efterpi Kostareli, Maria Gounari, Andreas Agathangelidis, Kostas Stamatopoulos

  e2012052

  2012-08-09

  https://doi.org/10.4084/mjhid.2012.052

  3240

  PDF: 956

  HTML: 7317

  Kost Fig1: 233

  Kost Fig 2: 220

  Kost Fig3: 234

  Kost Fig 4: 245

  Kost Fig5: 240

  Kost fig 6: 229

• THE SPECTRUM OF GENETIC DEFECTS IN CHRONIC LYMPHOCYTIC LEUKEMIA

  Davide Rossi, Marco Fangazio, Gianluca Gaidano

  e2012076

  2012-11-13

  https://doi.org/10.4084/mjhid.2012.076

  2374

  PDF: 944

  HTML: 2022

  Fig 1 Rossi: 249

• LYMPHOCYTES IN PATIENTS WITH CHRONIC ACTIVE EPSTEIN-BARR VIRUS INFECTION EXHIBITED ELEVATED PD-1/PD-L1 EXPRESSION AND A PREVAILING TH2 IMMUNE RESPONSE. EPSTEIN-BARR VIRUS INFECTION EXHIBITED ELEVATED PD-1/PD-L1

  kang sun

  e2024037

  2024-04-30

  https://doi.org/10.4084/MJHID.2024.037

  3055

  PDF: 1177

  HTML: 136

• APPLICATION OF NEW DRUGS IN CHRONIC LYMPHOCYTIC LEUKEMIA

  Tadeusz Robak

  e2010011

  2010-05-07

  https://doi.org/10.4084/mjhid.2010.011

  1741

  PDF: 698

  HTML: 2451

• PROGNOSTIC IMPACT OF IMMUNOHISTOCHEMICAL P53 EXPRESSION IN BONE MARROW BIOPSY IN HIGHER RISK MDS: A PILOT STUDY

  Alfredo Molteni, Emanuele Ravano, Marta Riva, Michele Nichelatti, Laura Bandiera, Lara Crucitti, Mauro Truini, Roberto Cairoli

  e2019015

  2019-02-26

  https://doi.org/10.4084/mjhid.2019.015

  1981

  PDF: 1040

  HTML: 354

• CONCISE REVIEW ON THE FREQUENCY, MAJOR RISK FACTORS AND SURVEILLANCE OF HEPATOCELLULAR CARCINOMA (HCC) IN ?-THALASSEMIAS: PAST, PRESENT AND FUTURE PERSPECTIVES Thalassaemia transfusion dependent, Hepatitis C, hepatocarcinoma.

  Vincenzo De Sanctis

  e2020006

  2020-01-01

  https://doi.org/10.4084/mjhid.2020.006

  4442

  PDF: 1609

  HTML: 481

• APLASTIC ANEMIA AND VIRAL HEPATITIS

  Laura Cudillo

  e2009026

  https://doi.org/10.4084/mjhid.2009.026

  1350

  PDF: 574

  HTML: 23235

• Burkitt lymphoma as fourth neoplasia in a patient affected by Cowden Syndrome with a novel PTEN germline pathogenic variant

  Eugenio Galli, Francesco D’Alò, Annarosa Cuccaro, Eleonora Alma, Elena Maiolo, Fulvia Brugnoletti, Luigi Maria Larocca, Marcella Zollino, Andrea Paolo Bacigalupo, Stefan Hohaus

  e2020034

  2020-06-28

  https://doi.org/10.4084/mjhid.2020.034

  1425

  PDF: 641

  HTML: 337

• Treating relapsed/refractory acute myeloid leukemia with chidamide, fludarabine, cytarabine and granulocyte-colony stimulating factor with subsequent bridging to myeloablative allogeneic hematopoietic stem cell transplantation Treating relapsed/refractory acute myeloid leukemia with chidamide, fludarabine, cytarabine and G-CSF

  Wen Yao, Xinchen Fang, Peng Jiang, Juan Tong, Liangquan Geng, Xiaoyu Zhu, Baolin Tang, Xiang Wan, Kaidi Song, Lei Zhang, Ping Qiang, Guangyu Sun, Yongsheng Han, Huilan Liu, Zimin Sun

  e2022025

  2022-02-27

  https://doi.org/10.4084/MJHID.2022.025

  1902

  PDF: 646

  HTML: 370

• ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN THERAPY-RELATED MYELOID NEOPLASMS (t-MN) OF THE ADULT: MONOCENTRIC OBSERVATIONAL STUDY AND REVIEW OF THE LITERATURE.

  Elisabetta Metafuni, Patrizia Chiusolo, Luca Laurenti, Federica Sorà, Sabrina Giammarco, Andrea Bacigalupo, Giuseppe Leone, Simona Sica

  e2018005

  2018-01-01

  https://doi.org/10.4084/mjhid.2018.005

  4335

  PDF: 1165

  HTML: 1457

• miR-155-5p PROMOTES CD34+ APOPTOSIS AND INHIBITS BONE MARROW HEMATOPOIESIS IN MYELODYSPLASTIC SYNDROMES BY RAC1/CREB/MIR-15B AXIS

  Meiwan Cao, BaoLing Peng, WanFu Xu, PeiYu Chen, Huan Chen, LiPing Ye, Jing Xie, HongLi Wang, Lu Ren, LiYa Xiong, JingNan Zhu, XiangYe Xu, LanLan Geng, SiTang Gong

  e2023040

  2023-06-29

  https://doi.org/10.4084/MJHID.2023.040

  857

  PDF: 949

  PDF Supp. Files: 112

  HTML: 265

• AN INEXPENSIVE CLINICAL-LABORATORY NOMOGRAM TO PREDICT POST-TREATMENT LUNG DESTRUCTION IN PULMONARY TUBERCULOSIS

  Min Xu, Jiahui He, Jianju Feng

  e2025075

  2025-10-31

  https://doi.org/10.4084/MJHID.2025.075

  726

  PDF: 369

  Suppl. Files: 99

  Html: 81

• TREATMENT OF INDOLENT AND ADVANCED SYSTEMIC MASTOCYTOSIS Systemic Mastocytosis Treatment

  Alessandro Buonomo, Eleonora Nucera, Marianna Criscuolo

  e2022040

  2022-04-28

  https://doi.org/10.4084/MJHID.2022.040

  2305

  PDF: 1671

  HTML: 705

• THE PRICE OF MERCY: COMMENT TO THE PAPER "PREVENTION OF BETA-THALASSEMIA IN NORTHERN ISRAEL - A COST-BENEFIT ANALYSIS” BY KOREN ET AL

  Eliezer Rachmilewitz

  e2014022

  2014-03-10

  https://doi.org/10.4084/mjhid.2014.022

  1588

  PDF: 1033

  HTML: 2135

• THERAPY-RELATED MYELOID NEOPLASMS: CONSIDERATIONS FOR PATIENTS’ CLINICAL EVALUATION. Clinical Evaluation of T-AML

  Dr. Palmieri, Ilaria Del Principe, Dr. Maurillo, Prof. Venditti, Francesco Buccisano

  e2023051

  2023-08-29

  https://doi.org/10.4084/MJHID.2023.051

  2240

  PDF: 899

  HTML: 268

• HIGHLIGHTS ON THE CONTRIBUTION OF GUT MICROBIOTA TO IMMUNE-MEDIATED DISEASES IN CHILDHOOD Gut microbiota in childhood immune-mediated diseases

  Donato Rigante, Helena Pelanda, Eleonora Rulli, Murad Sultanov, Susanna Adornato

  e2026025

  2026-02-28

  https://doi.org/10.4084/MJHID.2026.025

  1234

  PDF: 906

  HTML: 302

• NOVEL DRUGS IN FOLLICULAR LYMPHOMA

  Giuseppe Rossi, Antonella Anastasia

  e2016061

  2016-11-01

  https://doi.org/10.4084/mjhid.2016.061

  5926

  PDF: 1608

  HTML: 1677

  Untitled: 283

• DRUG THERAPY IN THE PROGRESSED CML PATIENT WITH MULTI-TKI FAILURE

  Ibrahim C. Haznedaroglu

  e2015014

  2015-12-02

  https://doi.org/10.4084/mjhid.2015.014

  277870

  PDF: 1889

  HTML: 3908

• Guest Editor: Pellegrino Musto REFINING HIGH-RISK MULTIPLE MYELOMA: ADVANCEMENTS IN GENOMIC, CLINICAL, AND PROGNOSTIC CRITERIA Multiple Myeloma High Risk Classificatio

  Dr. Enrica A. Martino, Dr. G. Mele, Dr. F. Morabito, Dr. M. Gentile, Dr. E. Vigna

  e2025006

  2024-12-31

  https://doi.org/10.4084/MJHID.2025.006

  2328

  PDF: 1702

  HTML: 694